ORL 2022
  • Thank You!
    • 2022 Conference Photos
  • Programme
    • Tue 25 Oct
    • Wed 26 Oct
    • Thu 27 Oct
    • Fri 28 Oct
    • Posters On Display
  • Speakers
    • Our Speakers
    • 2022 Presentations
  • Sponsorship & Exhibition
    • Our Supporters
  • Useful Links
  • Contact
  • Thank You!
    • 2022 Conference Photos
  • Programme
    • Tue 25 Oct
    • Wed 26 Oct
    • Thu 27 Oct
    • Fri 28 Oct
    • Posters On Display
  • Speakers
    • Our Speakers
    • 2022 Presentations
  • Sponsorship & Exhibition
    • Our Supporters
  • Useful Links
  • Contact

A Modified Formulation of Zoono® Has Enhanced Efficacy against Bacterial Biofilms
Dr Sam Hale, ORL Registrar/PhD student, The University of Auckland, New Zealand

Authors List
  • Hale, S. J. M.
  • Lux, C. A.
  • Kim, R.
  • Biswas, K.
  • Wagner Mackenzie, B.
  • Douglas, R. G. 
(All authors are from the Department of Surgery, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand)

Introduction
The presence of sinonasal bacterial biofilms in chronic rhinosinusitis (CRS), particularly those composed of Staphylococcus aureus, are associated with greater severity and recalcitrance. However, there are few effective topical products available to treat them. Zoono® is a widely available quaternary ammonium compound-based hand sanitiser that may have antibiofilm efficacy. Accordingly, this agent has promise as a therapeutic agent for the management of biofilm-associated CRS.

Aim
To determine the efficacy of Zoono® and Zoono® B22-1402A formulation against S. aureus and P. aeruginosa biofilms grown in vitro.

Methods
Biofilms were grown using the Centers for Disease Control (CDC) biofilm reactor and the Calgary Biofilm Device. Biofilms grown in each model were treated for 5 mins, 1 hour, 6 hours or overnight in Zoono®, Zoono® B22-1402A, or 0.9% saline (control). Viable bacteria remaining after treatment were cultured and enumerated by colony counting.

Results
In biofilms grown in the CDC biofilm reactor, Zoono® caused minimal reductions in viable S. aureus at all timepoints. A 4.1 log10 reduction at 6 hours and 5.8 log10 reduction overnight in viable P. aeruginosa was observed compared to control. Treatment with Zoono® B22-1402A resulted in a 6.2 log10 reduction in viable S. aureus at 1 hour and eradication at 6 hours. Zoono® B22-1402A caused a 4.2 log10 reduction in viable P. aeruginosa at 5 min and near eradication by 1 hour.
In biofilms grown in the Calgary Biofilm Device, both formulations eradicated S. aureus biofilm by 1 hour. Zoono® B22-1402A eradicated P. aeruginosa biofilm at 1 hour, and Zoono® achieved near eradication at 6 hours.

 Conclusions
Both Zoono® formulations demonstrated antibiofilm activity, with Zoono® B22-1402A demonstrating greater potency. Biofilms grown in the Calgary Biofilm Device were more susceptible to the effects of antiseptics than those grown in the CDC biofilm reactor.
For any queries please contact our Professional Conference Organiser (PCO):
Donna Clapham

Workz4U Conference Management Ltd
Po Box 90641, Victoria Street West, Auckland 1142, NZ
+64 21 325 133 ~ conferences@w4u.co.nz ~ www.w4u.co.nz
Picture
ORL 2022 is the 75th Annual Scientific Meeting of the 
​The New Zealand Society of Otolaryngology,
Head & Neck Surgery

https://www.orl.org.nz/
​
Picture